|
1
|
Agrawal U, Rai H and Jain AK:
Morphological and ultrastructural characteristics of extracellular
matrix changes in oral squamous cell carcinoma. Indian J Dent Res.
22:16–21. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li-Ting C, Chung-Ho C, Yi-Hsin Y and
Pei-Shan H: The development and validation of oral cancer staging
using administrative health data. BMC Cancer. 14:3802014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li Y, Zhang J and Yang K: Evaluation of
the efficacy of a novel radical neck dissection preserving the
external jugular vein, greater auricular nerve and deep branches of
the cervical nerve. Onco Targets Ther. 6:361–367. 2013.PubMed/NCBI
|
|
4
|
Kurokawa H, Miura K, Yamashita Y, Tokudome
S, Murata T and Kajiyama M: Evaluation of neo-adjuvant chemotherapy
for oral squamous cell carcinoma. Gan To Kagaku Ryoho.
24:1273–1278. 1997.(In Japanese). PubMed/NCBI
|
|
5
|
Kawashiri S, Noguchi N, Tanaka A, Nakaya
H, Kato K and Yamamoto E: Inhibitory effect of neoadjuvant
chemotherapy on metastasis of oral squamous cell carcinoma in a
mouse model. Oral Oncol. 45:794–797. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Korogi Y, Hirai T, Nishimura R, Hamatake
S, Sakamoto Y, Murakami R, Baba Y, Arakawa A, Takahashi M, Uji Y,
et al: Superselective intraarterial infusion of cisplatin for
squamous cell carcinoma of the mouth: Preliminary clinical
experience. AJR Am J Roentgenol. 165:1269–1272. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Eckardt A, Kelber A and Pytlik C:
Palliative intra-arterial (i.a.) chemotherapy with carboplatin
(CBDCA) and 5-FU in unresectable advanced (stage III and IV) head
and neck cancer using implantable port-systems. Eur J Surg Oncol.
21:486–489. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brockstein BE and Vokes EE: Oral
chemotherapy in head and neck cancer. Drugs. 58(Suppl 3): S91–S97.
1999. View Article : Google Scholar
|
|
9
|
Fuwa N, Kodaira T, Furutani K, Tachibana
H, Nakamura T and Daimon T: Chemoradiation therapy using
radiotherapy, systemic chemotherapy with 5-fluorouracil and
nedaplatin and intra-arterial infusion using carboplatin for
locally advanced head and neck cancer - Phase II study. Oral Oncol.
43:1014–1020. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Y, Yang K, Ji P, Zhang F, Chen R and
Deng D: Regional arterial infusion chemotherapy for the treatment
of oral squamous cell carcinoma(OSCC). Shanxi Med J. 35:529–530.
2006.(In Chinese).
|
|
11
|
Li Y, Yang K, Zhang J, Zhang F, Chen R and
Deng D: Clinical study of chron-chemotherapy together with arterial
chemotherapy for oral and maxillofacial squamous cell carcinoma.
Kouqiang Yi Xue Yan Jiu. 23:668–670. 2007.(In Chinese).
|
|
12
|
Muller PA and Vousden KH: Mutant p53 in
cancer: New functions and therapeutic opportunities. Cancer Cell.
25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu Y, Liu X, Yang Y, Zhao X, Xue J, Zhang
W and Yang A: Effect of FHIT loss and p53 mutation on HPV-infected
lung carcinoma development. Oncol Lett. 10:392–398. 2015.PubMed/NCBI
|
|
14
|
Li Z, Sun Y, Chen X, et al: p53 mutation
directs AURKA overexpression via miR-25 and FBXW7 in prostatic
small cell neuroendocrine carcinoma. Mol Cancer Res. 13:584–591.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang L, Xiong H, Wu F, et al: Hexokinase
2-mediated Warburg effect is required for PTEN- and
p53-deficiency-driven prostate cancer growth. Cell Rep.
8:1461–1474. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Martin L, Grigoryan A, Wang D, et al:
Identification and characterization of small molecules that inhibit
nonsense-mediated RNA decay and suppress nonsense p53 mutations.
Cancer Res. 74:3104–3113. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gibbons DL, Byers LA and Kurie JM:
Smoking, p53 mutation, and lung cancer. Mol Cancer Res. 12:3–13.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Harrington EA, Bruce JL, Harlow E and
Dyson N: pRB plays an essential role in cell cycle arrest induced
by DNA damage. Proc Natl Acad Sci USA. 95:11945–11950. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lam AK, Chan SS and Leung M: Synchronous
colorectal cancer: Clinical, pathological and molecular
implications. World J Gastroenterol. 20:6815–6820. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng T, Yin D, Lu Z, et al: Nutlin-3
overcomes arsenic trioxide resistance and tumor metastasis mediated
by mutant p53 in Hepatocellular Carcinoma. Mol Cancer. 13:1332014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bykov VJ and Wiman KG: Mutant p53
reactivation by small molecules makes its way to the clinic. FEBS
Lett. 588:2622–2627. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mazumdar M, Smith A and Schwartz LH: A
statistical simulation study finds discordance between WHO criteria
and RECIST guideline. J Clin Epidemiol. 57:358–365. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pindborg JJ, Reichart PA, Smith CJ and van
der Waal I: World Health Organisation Histological Classification
of Tumours. Histological Typing of Cancer and Precancer of the Oral
Mucosa (2nd). Springer-Verlag. (Berlin). 1997. View Article : Google Scholar
|
|
24
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumours (7th). Wiley-Blackwell.
Chichester: 2009.
|
|
25
|
Rybanska I, Ishaq O, Chou J, et al: PARP1
and DNA-PKcs synergize to suppress p53 mutation and telomere
fusions during T-lineage lymphomagenesis. Oncogene. 32:1761–1771.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Decastel M, Ossondo M, Andrea AM, et al:
Colorectal cancer in patients seen at the teaching hospitals of
Guadeloupe and Martinique: Discrepancies, similarities in
clinicopathological features, and p53 status. BMC Clin Pathol.
14:122014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Imamura H, Ohishi Y, Aman M, et al:
Ovarian high-grade serous carcinoma with a noninvasive growth
pattern simulating a serous borderline tumor. Hum Pathol. Jun
16–2015.((Epub ahead of print)). PubMed/NCBI
|
|
28
|
Jasar Dz, Smichkoska S, Kubelka K, et al:
Expression of p53 protein product in triple negative breast cancers
and relation with clinical and histopathological parameters.
Prilozi. 36:69–79. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tan PH, Jayabaskar T, Yip G, et al: p53
and c-kit (CD117) protein expression as prognostic indicators in
breast phyllodes tumors: A tissue microarray study. Mod Pathol.
18:1527–1534. 2005.PubMed/NCBI
|
|
30
|
Reiher F, Ozer O, Pins M, et al: p53 and
microvessel density in primary resection specimens of superficial
bladder cancer. J Urol. 167:1469–1474. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang H, Bao W, Jiang F, et al: Mutant p53
(p53-R248Q) functions as an oncogene in promoting endometrial
cancer by up-regulating REGγ. Cancer Lett. 360:269–279. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang K, Chen L, Zhang J, et al: Elevated
p53 expression levels correlate with tumor progression and poor
prognosis in patients exhibiting esophageal squamous cell
carcinoma. Oncol Lett. 8:1441–1446. 2014.PubMed/NCBI
|
|
33
|
Yang Y, Zhen T, Zhang F, et al: p53 and
hepatoma-derived growth factor expression and their
clinicopathological association with Ewing family tumour. J Clin
Pathol. 67:235–242. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Karim S: Clinicopathological and p53 gene
alteration comparison between young and older patients with gastric
cancer. Asian Pac J Cancer Prev. 15:1375–1379. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wu Z, Han X, Qin S, et al: Interleukin 1
receptor antagonist reduces lethality and intestinal toxicity of
5-Fluorouracil in a mouse mucositis model. Biomed Pharmacother.
65:339–344. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu J, Xu H, Zhang L and Zhang X: Radix
astragali and tanshinone help Carboplatin inhibit B16 tumor cell
growth. Technol Cancer Res Treat 2015. Jun 3–2015.((Epub ahead of
print))
|
|
37
|
Gao J, Gao J, Qian L, et al: Activation of
p38-MAPK by CXCL4/CXCR3 axis contributes to p53-dependent
intestinal apoptosis initiated by 5-fluorouracil. Cancer Biol Ther.
15:982–991. 2014. View Article : Google Scholar : PubMed/NCBI
|
